Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Epilepsy

Vigabatrin treatment and visual field loss

Nature Reviews Neurology volume 7, pages 189–190 (2011)Cite this article

Subjects

Vigabatrin is an efficacious new-generation antiepileptic drug, but visual field loss (VFL) has strongly limited its use. A systematic review has established that vigabatrin increases the risk of VFL fourfold, with age and exposure as predicting factors. For infantile spasms, the benefits of vigabatrin seem to outweigh the VFL risk.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lux, A. L. et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 4, 712–717 (2005).

    Article  CAS  Google Scholar 

  2. Chiron, C., Dumas, C., Jambaque, I., Mumford, J. & Dulac, O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 26, 389–395 (1997).

    Article  CAS  Google Scholar 

  3. Jambaque, I., Chiron, C., Dumas, C., Mumford, J. & Dulac, O. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res. 38, 151–160 (2000).

    Article  CAS  Google Scholar 

  4. Maguire, M. J., Hemming, K., Wild, J. M., Hutton, J. L. & Marson, A. G. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 51, 2423–2431 (2010).

    Article  Google Scholar 

  5. Gaily, E., Jonsson, H. & Lappi, M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia 50, 206–216 (2009).

    Article  CAS  Google Scholar 

  6. Lawthom, C., Smith, P. E. & Wild, J. M. In utero exposure to vigabatrin: no indication of visual field loss. Epilepsia 50, 318–321 (2009).

    Article  Google Scholar 

  7. Westall, C. A. et al. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc. Ophthalmol. 107, 299–309 (2003).

    Article  Google Scholar 

  8. Lawthom, C., Smith, P. E. & Wild, J. M. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Ophthalmology 116, 565–571 (2009).

    Article  Google Scholar 

  9. Kroll-Seger, J. et al. Severe relapse of epilepsy after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms? Epilepsia 48, 612–613 (2007).

    Article  Google Scholar 

  10. Nabbout, R., Melki, I., Gerbaka, B., Dulac, O. & Akatcherian, C. Infantile spasms in Down syndrome: good response to a short course of vigabatrin. Epilepsia 42, 1580–1583 (2001).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inserm U663,

    Catherine Chiron & Olivier Dulac

  2. APHP, Necker Hospital,

    Catherine Chiron & Olivier Dulac

  3. University Paris Descartes, 149 rue de Sevres, 75015, Paris, France

    Catherine Chiron & Olivier Dulac

Authors
  1. Catherine Chiron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivier Dulac
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine Chiron.

Ethics declarations

Competing interests

C. Chiron provided expert opinion for vigabatrin to Sanofi-Aventis. O. Dulac declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiron, C., Dulac, O. Vigabatrin treatment and visual field loss. Nat Rev Neurol 7, 189–190 (2011). https://doi.org/10.1038/nrneurol.2011.25

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2011.25

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing